A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma

Emilio Bajetta(Fondazione Lanza), Natale Cascinelli, Paola Queirolo, T. Cainelli(Azienda Ospedaliero-Universitaria delle Marche), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Milena Vitali(Sorbonne Université), Leonardo Ferrari(Fondazione IRCCS Istituto Nazionale dei Tumori), Mario Roberto Sertoli(Ente Ospedaliero Ospedali Galliera), R. Cellerino, Antonia Martinetti(Cochlear (Australia))
Tumori Journal
July 1, 2001
10.1177/030089160108700402
Cited by 11

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780